We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
-0.94%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$498M
AUM Growth
-$33M
Cap. Flow
+$1.65M
Cap. Flow %
0.33%
Top 10 Hldgs %
75.53%
Holding
33
New
4
Increased
9
Reduced
10
Closed
4

Top Buys

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$14.8M
2
ACHN
Achillion Pharmaceuticals
ACHN
+$12.9M
3
FATE icon
Fate Therapeutics
FATE
+$10.1M
4
INFI
Infinity Pharmaceuticals, Inc.
INFI
+$3.54M
5
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$2.96M

Top Sells

Rank Stock Value
1
TBRA
Tobira Therapeutics, Inc. Common Stock
TBRA
+$15.9M
2
ARRY
Array Biopharma Inc
ARRY
+$10.9M
3
CLCD
CoLucid Pharmaceuticals, Inc.
CLCD
+$9.87M
4
PTGX icon
Protagonist Therapeutics
PTGX
+$7.92M
5
CCXI
ChemoCentryx, Inc.
CCXI
+$1.91M

Sector Composition

Rank Sector Weight
1 Healthcare 76.75%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BPMC
1
DELISTED
Blueprint Medicines
BPMC
$91.3M 18.35%
3,255,280
+490,200
+18% +$14.8M
CYTK icon
2
Cytokinetics
CYTK
$10.9B
$58.9M 11.84%
4,851,691
-145,380
-3% -$1.54M
CCXI
3
DELISTED
ChemoCentryx, Inc.
CCXI
$57.7M 11.59%
7,798,572
-265,447
-3% -$1.91M
ARRY
4
DELISTED
Array Biopharma Inc
ARRY
$43.8M 8.81%
4,986,186
-1,475,000
-23% -$10.9M
CNCE
5
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$26.9M 5.41%
2,616,249
-106,961
-4% -$978K
XENE icon
6
Xenon Pharmaceuticals
XENE
$6.2B
$23.4M 4.71%
3,043,805
-65,100
-2% -$523K
FWP
7
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
$20.8M 4.19%
198,265
– –
CTIC
8
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$18.1M 3.63%
4,479,694
– –
CLCD
9
DELISTED
CoLucid Pharmaceuticals, Inc.
CLCD
$17.6M 3.54%
484,335
-278,965
-37% -$9.87M
CBIO
10
Crescent Biopharma
CBIO
$555M
$17.2M 3.46%
28,263
+4,000
+16% +$2.5M
OMED
11
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
$13.6M 2.73%
1,760,489
-51,516
-3% -$473K
CASC
12
DELISTED
Cascadian Therapeutics, Inc.
CASC
$13.5M 2.71%
3,133,224
-4
-0% -$26
INFI
13
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$10.6M 2.13%
7,860,808
+2,711,164
+53% +$3.54M
ACHN
14
DELISTED
Achillion Pharmaceuticals
ACHN
$10M 2.01%
+2,423,300
New +$12.9M
FATE icon
15
Fate Therapeutics
FATE
$293M
$9.44M 1.9%
+3,759,398
New +$10.1M
ARQL
16
DELISTED
Arqule Inc
ARQL
$9.32M 1.87%
7,400,128
– –
ESPR
17
DELISTED
Esperion Therapeutics
ESPR
$8.92M 1.79%
712,770
+218,898
+44% +$2.61M
KDNY
18
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$8.5M 1.71%
149,177
+48,946
+49% +$2.96M
IMDZ
19
DELISTED
Immune Design Corp.
IMDZ
$7.26M 1.46%
1,320,164
+120,164
+10% +$849K
CTMX icon
20
CytomX Therapeutics
CTMX
$714M
$6.1M 1.23%
554,806
-37,007
-6% -$448K
ONCT
21
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
$5.85M 1.18%
7,917
-306
-4% -$327K
VIRX
22
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$5.04M 1.01%
39,792
+18,925
+91% +$2.63M
ALPN
23
DELISTED
Alpine Immune Sciences Inc
ALPN
$4.18M 0.84%
466,119
+38,701
+9% +$771K
PVLA
24
Palvella Therapeutics
PVLA
$2.15B
$2.61M 0.52%
23,185
+10,478
+82% +$1.3M
FLNA
25
Filana Therapeutics
FLNA
$46.4M
$1.3M 0.26%
325,507
– –
1
2

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q4 2016 Portfolio in Review

As of Q4 2016, BVF Inc held 33 positions worth $498M, down 6.2% from $531M the previous quarter. Its ten largest holdings account for 76% of the portfolio.

BVF Inc's Q4 2016 filing shows 4 new, 9 increased, 10 reduced and 4 closed positions. Its largest new stake was Achillion Pharmaceuticals: 2,423,300 shares worth $10M. The largest sale was Tobira Therapeutics, Inc. Common Stock, an estimated $15.9M.

By sector, the portfolio is most concentrated in Healthcare at 77% of assets, down from 78% a quarter earlier.

  • BVF Inc's largest Q4 2016 buy was Achillion Pharmaceuticals: 2,423,300 shares worth $10M.
  • BVF Inc added most to Blueprint Medicines in Q4 2016, an estimated $14.8M increase.
  • BVF Inc's biggest Q4 2016 reduction was Array Biopharma Inc, cutting an estimated $10.9M.
  • BVF Inc fully exited Tobira Therapeutics, Inc. Common Stock in Q4 2016, selling an estimated $15.9M.
  • BVF Inc's ten largest holdings make up 76% of its $498M portfolio in Q4 2016.
  • BVF Inc opened 4 new positions and closed 4 in Q4 2016.
  • BVF Inc's portfolio value fell 6.2% quarter-over-quarter to $498M.

Based on BVF Inc's 13F filing for Q4 2016, filed 14 Feb 2017.